Hyundai Bioland현대바이오랜드
052260 · KOSDAQ · ₩052260 · 현대바이오랜드
₩4,260▲ ₩5 (0.12%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩131B | ₩120B | ₩102B | ₩99B | ₩103B |
| Cost of sales | ₩77B | ₩67B | ₩65B | ₩64B | ₩66B |
| Gross profit | ₩54B | ₩53B | ₩37B | ₩36B | ₩37B |
| Operating income | ₩13B | ₩16B | ₩7.1B | ₩9.1B | ₩11B |
| Net income | ₩253M | ₩5.7B | ₩8.1B | ₩4.8B | −₩12B |
| Net income to shareholders | ₩253M | ₩5.7B | ₩8.1B | ₩4.8B | −₩12B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩167B | ₩195B | ₩184B | ₩176B | ₩173B |
| Current assets | ₩92B | ₩107B | ₩80B | ₩71B | ₩64B |
| Cash and equivalents | ₩18B | ₩21B | ₩14B | ₩7.6B | ₩15B |
| Total liabilities | ₩31B | ₩57B | ₩48B | ₩47B | ₩47B |
| Current liabilities | ₩28B | ₩56B | ₩47B | ₩46B | ₩47B |
| Borrowings | ₩10B | ₩35B | ₩32B | ₩35B | ₩33B |
| Total equity | ₩136B | ₩138B | ₩136B | ₩129B | ₩125B |
| Shareholders' equity | ₩136B | ₩138B | ₩136B | ₩129B | ₩125B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩19B | ₩4.6B | ₩5.6B | ₩11B | ₩21B |
| Capital spending | ₩4B | ₩3.6B | ₩5.8B | ₩3.8B | ₩2.3B |
| Free cash flow | ₩15B | ₩957M | −₩179M | ₩7.5B | ₩19B |
| Dividends paid | ₩2.1B | ₩1.1B | ₩1.1B | ₩1.1B | ₩1.5B |
Consolidated where available. Amounts in won.
Also known as: Hyundai Bioland / 현대바이오랜드 / 052260 / KRX:052260
Source: KRX statistical information